Clinical trials
MDS clinical trials
Below are recruiting mds clinical trials, each written for real people, not researchers. We’re tracking 138 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03173937RecruitingPhase 1/Phase 2
Cord blood transplant for severe aplastic anemia or MDS
This trial tests a special type of cord blood transplant using lab-grown stem cells to help the new blood-forming cells “take” sooner. It’s for people with severe aplastic anemia or certain MDS cases who have not responded well to standard immune-suppressing treatments.
Bethesda, MarylandAges 4–75 - NCT06465953RecruitingPhase 3
Ivosidenib vs azacitidine for IDH1-mutated MDS
This trial tests if the drug ivosidenib alone or azacitidine alone can help people with a specific type of MDS that has an IDH1 mutation. It is for people who have not had strong MDS treatments yet.
Denver, ColoradoAges 18 years+ - NCT04184505RecruitingPhase 3
Testing stem cell transplant in higher-risk myelodysplastic syndrome
This Phase 3 trial tests whether doing an “allogeneic” stem cell transplant works best for people newly diagnosed with higher-risk MDS (a bone marrow disorder). It’s mainly for patients who are healthy enough to receive a transplant and haven’t started MDS treatment yet.
AlessandriaAges 18–70 - NCT04061239RecruitingPhase 2
New treatment options before stem cell transplant for higher-risk MDS/AML
This Phase 2 trial compares treatment approaches for people with higher-risk MDS or a specific type of AML before they get a stem cell transplant. The goal is to see which approach helps you get ready for transplant more safely and effectively.
LinzAges 18–75 - NCT07006025RecruitingPhase 1
Oral THU-decitabine for MDS that has returned or not improved
This trial tests an oral combination of two drugs (THU and decitabine) for people with myelodysplastic syndromes (MDS) whose disease has come back or not responded to at least one prior standard treatment. The goal is to see if it can help control the disease.
The Bronx, New YorkAges 18 years+ - NCT04365179RecruitingPhase 1
NEROFE for advanced MDS or AML after other treatments
This early-phase trial tests NEROFE, a hormone-peptide medicine, in adults with advanced myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back or did not respond. It aims to see if NEROFE is safe and can help patients whose disease is unlikely to benefit from standard remaining options.
Miami, FloridaAges 18 years+ - NCT03520647RecruitingPhase 2
Haplo transplant for severe bone marrow failure using donor cells
This trial tests a stem cell transplant from a closely matched but not fully matched family donor (haploidentical), with chemotherapy after the transplant to help prevent graft-versus-host disease (GVHD). It may help people with severe aplastic anemia, certain MDS after transformation, or PNH when other treatments have not worked or are not available.
Bethesda, MarylandAges 4–75 - NCT04275518RecruitingPhase 1
Trial for relapsed leukemia or risky MDS with new drug
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04869683Recruiting
Collecting blood and tissue samples in myelodysplastic syndrome
This trial collects and stores biological samples (like blood or other lab materials) from people with myelodysplastic syndrome, to help researchers learn more about the disease. It may help future diagnosis or treatments, even if it doesn’t directly test a new medicine.
BrestAges 18 years+ - NCT05025098RecruitingPhase 2
Targeted treatment versus standard care for older blood cancer patients
This Phase 2 trial compares a “precision” treatment plan with standard therapy for older adults with AML or MDS. It aims to improve outcomes while using treatments that may be better suited for people who cannot have intensive chemotherapy.
LørenskogAges 60 years+ - NCT05143996RecruitingPhase 1
First study drug for relapsed AML or MDS
This Phase 1 trial tests CLN-049 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or did not respond to treatment. The goal is to find out how well the drug can work and how safe it is in people with limited options.
Birmingham, AlabamaAges 18 years+ - NCT05181735RecruitingPhase 1/Phase 2
Testing luspatercept for low-risk MDS with low hemoglobin
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
AmiensAges 18 years+ - NCT06270771Recruiting
Using a wearable ring to monitor MDS patients at home
This study tests if people with MDS can comfortably wear the OURA ring (a smart ring) at home to track their health. The goal is to see if this is a useful way to monitor symptoms and well-being between doctor visits.
Toronto, OntarioAges 18 years+ - NCT06548230RecruitingPhase 1/Phase 2
Nadunolimab plus azacitidine for MDS and AML
This trial tests a new combination of drugs (nadunolimab plus azacitidine, sometimes with venetoclax) for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has not been treated much or has come back. The goal is to see if this combination can control the disease better.
Houston, TexasAges 18 years+ - NCT06552416RecruitingPhase 1
Safety study of MT-401-OTS for relapsed AML or MDS
This trial tests a new cell therapy called MT-401-OTS for people aged 65 or older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The goal is to see if this treatment is safe and to find the right dose.
Duarte, CaliforniaAges 65 years+ - NCT06614595Recruiting
Transfusion and quality of life in lower-risk MDS
This study looks at how well transfusions work and how they affect quality of life in people with lower-risk MDS who need regular blood transfusions. The goal is to find what predicts a good transfusion response and to improve care.
Oviedo, Principality of AsturiasAges 18 years+ - NCT06680752RecruitingPhase 1/Phase 2
A car-t cell therapy trial for AML or MDS
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
Charlotte, North CarolinaAges 18 years+ - NCT06681363Recruiting
Leukemia and MDS biobank study at Nantes Hospital
This trial creates a biobank of blood or bone marrow samples from patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or high-risk myelodysplastic syndrome (MDS). It aims to collect samples for future research, which may help develop better treatments.
NantesAges 18 years+ - NCT06704152RecruitingPhase 1/Phase 2
A cell therapy for blood cancers after stem cell transplant
This trial tests a new cell therapy (BSB-1001) given after a stem cell transplant to prevent or treat high-risk blood cancers like AML, ALL, or MDS. It is for patients with a specific genetic marker and a matched donor.
Duarte, CaliforniaAges 18–70 - NCT07384715RecruitingPhase 1
GEN3018 for AML or high-risk MDS
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
AarhusAges 18 years+ - NCT06892223RecruitingPhase 2
Anti-NKG2A antibody for leukemia or MDS after half-matched transplant
This trial tests a drug that targets NKG2A, a protein that may help prevent cancer cells from hiding from the immune system. It is for people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related conditions who have already received a half-matched stem cell transplant (haploidentical transplant) with a specific anti-rejection drug plan.
Genova, GENOVAAges 18–99 - NCT07081087Recruiting
Can a blood test replace bone marrow biopsy for low blood counts?
This study tries to see if blood tests can replace a bone marrow biopsy for people with low blood counts (cytopenia) and suspected MDS (myelodysplastic syndrome). It aims to make diagnosis less invasive by using a simple blood draw instead of a bone marrow sample.
San Diego, CaliforniaAges 18 years+ - NCT07096297RecruitingPhase 2
Testing two drugs for lower-risk MDS
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
New Haven, ConnecticutAges 18 years+ - NCT07328191Recruiting
Transfusion guided by quality of life for MDS or AML
This study is for people with MDS or AML who are not receiving treatment to cure the disease and need regular blood transfusions. It looks at whether using a quality-of-life questionnaire can guide transfusion decisions, to see if fewer transfusions can keep you feeling well.
NiceAges 18 years+
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
MDS trials by city
Studies with a site in or near these metro areas.
MDS trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for mds?
- Yes. Clin2 currently lists 138 recruiting mds studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mds trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mds trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.